Ben Zeskind, PhD, MBA
Ben Zeskind earned a PhD in Bioengineering from MIT's Biological Engineering Department, awarded June 9, 2006. His work resulted in a first-author publication in Nature Methods: Nucleic acid and protein mass mapping by live-cell deep-ultraviolet microscopy, two issued U.S. Patents: "Method and apparatus for UV imaging" (U.S. Patent # 7,491,943), and "Method and apparatus for generating a circularly polarized illumination" (U.S. Patent # 7,335,874), and was profiled in the Whitehead Institute's Paradigm Magazine. He subsequently earned an MBA at Harvard Business School, graduating as a Baker Scholar -- the highest award for distinction. He has authored a contributed paper on Deep Ultraviolet Microscopy and its Application to Cancer Immunology, and co-authored A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers." He is the founder and CEO of Immuneering Corporation, a company developing groundbreaking patient stratification technology to pre-identify patients who will respond to specific therapies, and ultimately make it easier to develop therapies that trigger an immune response to eliminate a patient's cancer. Immuneering was profiled in a recent article in Mass High Tech, Immuneering tests another path for personalized medicine.